Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences
REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) (“Coherus”) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) (“Junshi Biosciences”) intends to make a strategic investment of $50 million in Coherus pursuant to the terms of the definitive stock purchase agreement.
“We view our collaboration with Coherus as a strategic long-term partnership for the development and commercialization of toripalimab and promising PD-1 combination candidates,” said Dr. Ning LI, CEO of Junshi Biosciences. “We wanted to invest in Coherus so we could share our future growth together and mutual success with these programs.”
(2)
REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) ( Coherus ) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) ( Junshi Biosciences ) intends to make a strategic investment of $50 million in Coherus pursuant to the terms of the definitive stock purchase agreement. We view our collaboration with Coherus as a strategic long-term partnership for the development and commercialization of toripalimab and promising PD-1 combination candidates, said Dr. Ning LI, CEO of Junshi Biosciences. We wanted to invest in Coherus so we could share our future growth together and mutual success with these programs.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi .
Coherus BioSciences, Inc.February 1, 2021 GMT
- Coherus to pay $150 million upfront for U.S. and Canada rights to toripalimab, an extensively studied, late-stage anti-PD-1 antibody
- First U.S. BLA filing expected this year for nasopharyngeal carcinoma with breakthrough therapy designation
- Options to PD-1 combination agents, TIGIT and IL-2, add long-term growth potential
- Conference call at 8:00 am Eastern Time today
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced a collaboration with Shanghai Junshi Biosciences, Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) for the development and commercialization of toripalimab, Junshi Biosciences’ anti-PD-1 antibody, in the United States and Canada. U
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 .
Junshi BiosciencesFebruary 1, 2021 GMT
Junshi Biosciences to receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option programs (if exercised) in US and Canada
The first toripalimab BLA to be filed with the US FDA for nasopharyngeal carcinoma later this year
SHANGHAI, China, Feb. 01, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, today announced a collaboration with Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) for the development and commercialization of toripalimab, Junshi Biosciences’ anti-PD-1 antibody, in the Un
Junshi Biosciences
Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada
Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada
Junshi Biosciences to receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option programs (if exercised) in US and Canada
The first toripalimab BLA to be filed with the US FDA for nasopharyngeal carcinoma later this year
SHANGHAI, China, Feb. 01, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, today announced a collaboration with Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) for the development and commercialization of torip